NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan.
Proof of principle needed before launching “big science” program, advisors say.
Also in this 12-page issue: NCI’s Lance Liotta and FDA’s Emanuel Petricoin to move to George Mason University.
Zvi Fuks of Memorial Sloan-Kettering arrested and charged with securities fraud related to sale of ImClone stock.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









